Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $40.7 billion.

  • Teva Pharmaceutical Industries' Liabilities and Shareholders Equity rose 361.59% to $40.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $159.2 billion, marking a year-over-year decrease of 365.93%. This contributed to the annual value of $40.7 billion for FY2025, which is 361.59% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Liabilities and Shareholders Equity of $40.7 billion as of Q4 2025, which was up 361.59% from $39.9 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Liabilities and Shareholders Equity's 5-year high stood at $49.2 billion during Q2 2021, with a 5-year trough of $38.4 billion in Q1 2025.
  • For the 5-year period, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity averaged around $43.6 billion, with its median value being $43.3 billion (2023).
  • In the last 5 years, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity tumbled by 1143.32% in 2021 and then soared by 361.59% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Liabilities and Shareholders Equity stood at $47.7 billion in 2021, then decreased by 7.67% to $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then fell by 9.55% to $39.3 billion in 2024, then grew by 3.62% to $40.7 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $40.7 billion for Q4 2025, versus $39.9 billion for Q3 2025 and $40.1 billion for Q2 2025.